4.7 Review

Autophagy and polyglutamine diseases

Journal

PROGRESS IN NEUROBIOLOGY
Volume 97, Issue 2, Pages 67-82

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pneurobio.2011.08.013

Keywords

Polyglutamine diseases; Autophagy; Neurodegeneration; Huntington's disease

Categories

Funding

  1. MRC
  2. Wellcome Trust
  3. Wellcome Trust/MRC
  4. BBSRC/Lilly
  5. NIHR Biomedical Research Centre at Addenbrooke's Hospital
  6. Medical Research Council [G0600194] Funding Source: researchfish
  7. MRC [G0600194] Funding Source: UKRI

Ask authors/readers for more resources

In polyglutamine diseases, an abnormally elongated polyglutamine tract results in protein misfolding and accumulation of intracellular aggregates. The length of the polyglutamine expansion correlates with the tendency of the mutant protein to aggregate, as well as with neuronal toxicity and earlier disease onset. Although currently there is no effective cure to prevent or slow down the progression of these neurodegenerative disorders, increasing the clearance of mutant proteins has been proposed as a potential therapeutic approach. The ubiquitin-proteasome system and autophagy are the two main degradative pathways responsible for eliminating misfolded and unnecessary proteins in the cell. We will review some of the studies that have proposed autophagy as a strategy to reduce the accumulation of polyglutamine-expanded protein aggregates and protect against mutant protein neurotoxicity. We will also discuss some of the currently known mechanisms that induce autophagy, which may be beneficial for the treatment of these and other neurodegenerative disorders. (C) 2011 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available